brodalumab 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
human origin	5179	1174395-19-7

Description:

Molecule	Description
Synonyms: kyntheum brodalumab AMG 827 AMG-827	Brodalumab is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer and IL-25. IL-17RA is a protein expressed on the cell surface and is a required component of receptor complexes utilized by multiple IL-17 family cytokines. Blocking IL17RA inhibits IL-17 cytokine-induced responses including the release of pro-inflammatory cytokines and chemokines. Molecular weight: Formula: CLOGP: LIPINSKI: None HAC: None HDO: None TPSA: ALOGS: ROTB: None

Molecule

Description

Synonyms:

kyntheum
brodalumab
AMG 827
AMG-827

Brodalumab is a human monoclonal IgG2 antibody that selectively binds to human IL-17RA and inhibits its interactions with cytokines IL-17A, IL-17F, IL-17C, IL-17A/F heterodimer and IL-25. IL-17RA is a protein expressed on the cell surface and is a required component of receptor complexes utilized by multiple IL-17 family cytokines. Blocking IL17RA inhibits IL-17 cytokine-induced responses including the release of pro-inflammatory cytokines and chemokines.

Molecular weight:
Formula:
CLOGP:
LIPINSKI: None
HAC: None
HDO: None
TPSA:
ALOGS:
ROTB: None

Drug dosage:

Dose	Unit	Route
15	mg	P

ADMET properties:

None

Approvals:

Date	Agency	Company
July 17, 2017	EMA	LEO Pharma A/S
Feb. 15, 2017	FDA	VALEANT LUXEMBOURG
July 4, 2016	PMDA

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriatic arthropathy	62.90	47.34	21	413	47011	50557679
Collagen-vascular disease	48.21	47.34	6	428	78	50604612

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriatic arthropathy	75.08	42.72	24	779	14667	29559057
Dermatitis infected	64.01	42.72	9	794	91	29573633
Tinea pedis	54.17	42.72	11	792	1082	29572642
Peripheral venous disease	45.89	42.72	11	792	2317	29571407
Therapy interrupted	44.01	42.72	14	789	8372	29565352

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Psoriatic arthropathy	88.64	34.41	33	1248	43248	64454203
Dermatitis infected	59.83	34.41	9	1272	208	64497243
Tinea pedis	56.27	34.41	12	1269	2049	64495402
Psoriasis	45.41	34.41	24	1257	71679	64425772
Collagen-vascular disease	43.98	34.41	6	1275	67	64497384
Drug ineffective	39.61	34.41	64	1217	840183	63657268
Peripheral venous disease	38.35	34.41	11	1270	6327	64491124
Therapy interrupted	36.32	34.41	14	1267	20022	64477429
Suicidal ideation	35.80	34.41	20	1261	66522	64430929
Parakeratosis	34.50	34.41	6	1275	349	64497102

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	L04AC12	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS IMMUNOSUPPRESSANTS IMMUNOSUPPRESSANTS Interleukin inhibitors
FDA CS	M0001357	Antibodies, Monoclonal
MeSH PA	D003879	Dermatologic Agents
FDA EPC	N0000193276	Interleukin-17 Receptor A Antagonist
FDA MoA	N0000193279	Interleukin 17 Receptor A Antagonists

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID
Plaque psoriasis	indication	200965009
Non-radiographic axial spondyloarthritis	indication	713777005
Crohn's disease	contraindication	34000006

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

None

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Interleukin-17 receptor	Membrane receptor	Q96F46 Q8NAC3	I17RA_HUMAN I17RC_HUMAN	ANTIBODY BINDING	Kd	9.20		IUPHAR	SCIENTIFIC LITERATURE

External reference:

ID	Source
6ZA31Y954Z	UNII
4036541	VANDF
C3491331	UMLSCUI
CHEMBL1742996	ChEMBL_ID
D10061	KEGG_DRUG
DB11776	DRUGBANK_ID
9475	INN_ID
7540	IUPHAR_LIGAND_ID
1872251	RXNORM
32390	MMSL
d08529	MMSL
726519005	SNOMEDCT_US
763604008	SNOMEDCT_US
017103	NDDF
C571216	MESH_SUPPLEMENTAL_RECORD_UI

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Siliq	HUMAN PRESCRIPTION DRUG LABEL	1	0187-0004	INJECTION	210 mg	SUBCUTANEOUS	BLA	27 sections